Progress in the development of matrix metalloproteinase inhibitors

被引:88
|
作者
Tu, GuoGang [1 ,2 ]
Xu, WenFang
Huang, HuiMing [2 ]
Li, ShaoHua [2 ]
机构
[1] Shandong Univ, Dept Med Chem, Sch Pharmaceut Sci, Jinan 250012, Peoples R China
[2] NanChang Univ, Coll Med, Dept Pharm, Nanchang 330006, Peoples R China
关键词
matrix metalloproteinases; MMP inhibitors; Zinc-binding groups; cancer; computer-aided drug design; angiogenesis; metastasis; proteases;
D O I
10.2174/092986708784567680
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Matrix metalloproteinases ( MMPs) are a family of zinc-dependent proteinases involved in the degradation and remodeling of extracellular matrix proteins that are associated with the tumorigenic process. MMPs promote tumor invasion and metastasis, regulating host defense mechanisms and normal cell function. Thus, MMP inhibitors (MMPIs) are expected to be useful for the treatment of diseases such as cancer, osteoarthritis, and rheumatoid arthritis. A vast number of MMPIs have been developed in recent years. With the failure of these inhibitors in clinical trials, more efforts have been directed to the design of specific inhibitors with different Zn-binding groups. This review summarizes the current status of MMPIs, the design of small molecular weight MMPIs, a brief description of available three-dimensional MMP structures, a review of the proposed therapeutic utility of MMPIs, and a clinical update of compounds that have entered clinical trials in humans.
引用
收藏
页码:1388 / 1395
页数:8
相关论文
共 50 条
  • [41] Matrix metalloproteinase inhibitors in the treatment of cancer
    Brown, PD
    MEDICAL ONCOLOGY, 1997, 14 (01) : 1 - 10
  • [42] Matrix metalloproteinase inhibitors in rheumatic diseases
    Close, DR
    ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 : III62 - III67
  • [43] Matrix metalloproteinase inhibitors in the treatment of cancer
    Peter D. Brown
    Medical Oncology, 1997, 14 : 1 - 10
  • [44] Effect of matrix metalloproteinase inhibitors on atherogenesis
    Bashir, R
    Mazzola, P
    Lucca, D
    Grimes, G
    Jonas, E
    Saladino, C
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (02) : 270A - 271A
  • [45] New heteroarylbenzenesulphonamides as matrix metalloproteinase inhibitors
    Delbecq, F
    Cordonnier, G
    Pommery, N
    Barbry, D
    Hénichart, JP
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (05) : 1119 - 1121
  • [46] Enzyme activated matrix metalloproteinase inhibitors
    Jourden, Jody L. Major
    Cohen, Seth M.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
  • [47] Selective Matrix Metalloproteinase Inhibitors for Cancer
    Li, Nian-Guang
    Shi, Zhi-Hao
    Tang, Yu-Ping
    Duan, Jin-Ao
    CURRENT MEDICINAL CHEMISTRY, 2009, 16 (29) : 3805 - 3827
  • [48] Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer
    Bonomi, P
    SEMINARS IN ONCOLOGY, 2002, 29 (01) : 78 - 86
  • [49] Clinical Investigation of Matrix Metalloproteinases, Tissue Inhibitors of Matrix Metalloproteinases, and Matrix Metalloproteinase/Tissue Inhibitors of Matrix Metalloproteinase Complexes and Their Networks in Apical Periodontitis
    Martinho, Frederico C.
    Teixeira, Flavia F. C.
    Cardoso, Flavia G. R.
    Ferreira, Nadia S.
    Nascimento, Gustavo G.
    Carvalho, Claudio A. T.
    Valera, Marcia C.
    JOURNAL OF ENDODONTICS, 2016, 42 (07) : 1082 - 1088
  • [50] INOR 137-Co-crystallization studies for the development of matrix metalloproteinase inhibitors
    Lewis, Jana A.
    Cohen, Seth M.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232